Evaxion Biotech received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). The Notification Letter confirmed that the closing bid price of the Company’s American Depositary Shares has been at $1.00 per share or greater for ten consecutive business days from January 22, 2024, to February 02, 2024, and that the Company has regained compliance with the listing rules of the Nasdaq Capital Market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVAX:
- Evaxion Biotech Announces Pricing of $15 Million Public Offering
- Evaxion Biotech prices 3.75M ADSs at $4.00 in public offering
- Evaxion Biotech trading resumes
- Evaxion Biotech trading halted, volatility trading pause
- Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
